

restricted peptides of the Fel d I derived peptides described in Figure 9.

24. (Twice Amended) A peptide for use as an immunotherapeutic agent for desensitizing a patient to a polypeptide allergen capable of eliciting an allergic response in the patient, which patient possesses a particular MHC Class II molecule, selected by a method comprising (1) selecting a candidate peptide derived from the polypeptide allergen, (2) determining whether the candidate peptide demonstrates restriction to said MHC Class II molecule and (3) determining whether the candidate peptide is able to include a late phase response in an individual who possesses said MHC Class II molecule.

Please **add** claim 32.

32. (New) A peptide listed in a database of peptides characterized according to their ability to bind an MHC Class II molecule and induce a late phase response in an individual possessing said MHC Class II molecule.

Amendments to the claims are indicated in the attached "Marked Up Version of Amendments".

### **REMARKS**

Claims 1-12 and 15-31 are currently pending in the application. Claim 24 is amended. Claim 32 is added. Claims 1-7, 10, 12, 17-23, 25, and 26-31 are canceled without prejudice to pursuing these or related claims in one or more continuing applications. Support for the amended and added claims is found throughout the specification and in the claims as originally filed.

### **Formal Matters**

The Examiner has objected to the drawings in the present application for the reasons set forth in the Draftsperson's review. Specifically, the Draftsperson has requested that Figure 8 be relabeled SA and SB. Applicants submit herewith a new Figure 8, amended as required.